TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
35 hedge funds and large institutions have $24M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 5 closing their positions.
835% more call options, than puts
Call options by funds: $748K | Put options by funds: $80K
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
0% more funds holding
Funds holding: 35 → 35 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
5% less capital invested
Capital invested by funds: $25.4M → $24M (-$1.35M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
Linden Advisors
New York
|
+$429K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$382K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$252K |
| 4 |
Bank of New York Mellon
New York
|
+$144K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$70.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$457K |
| 2 |
Two Sigma Advisers
New York
|
-$309K |
| 3 |
Two Sigma Investments
New York
|
-$296K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$251K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$55K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MOS
26
MGO One Seven
Beachwood,
Ohio
| $31K | – | – | – |
|
27
Simplex Trading
Chicago,
Illinois
| $28K | +$7.14K | +142 | +35% |
|
28
Jane Street
New York
| $27K | +$26.1K | +520 | New |
|
29
UBS Group
Zurich,
Switzerland
| $13K | +$12.1K | +241 | New |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| $11K | +$10.1K | +200 | New |
|
31
Group One Trading
Chicago,
Illinois
| $9K | +$9.05K | +180 | New |
|
32
Morgan Stanley
New York
| $5K | +$1.36K | +27 | +39% |
|
33
Wells Fargo
San Francisco,
California
| $2K | -$1.11K | -22 | -33% |
|
|
TWA
34
TCI Wealth Advisors
Tucson,
Arizona
| $1K | – | – | – |
|
|
TRCT
35
Tower Research Capital (TRC)
New York
| $1K | +$654 | +13 | New |
|
|
36
Acadian Asset Management
Boston,
Massachusetts
| – | -$55K | -1,026 | Closed |
|
37
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$49.6K | -986 | Closed |
|
|
CBA
38
Coastal Bridge Advisors
Westport,
Connecticut
| – | -$32K | -595 | Closed |
|
39
Bank of America
Charlotte,
North Carolina
| – | -$2K | -39 | Closed |
|
|
TC
40
Truvestments Capital
Sarasota,
Florida
| – | -$1K | -16 | Closed |
|
TCON Hedge Fund Activity: Q1 2022 in Review
35 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q1 2022, worth a combined $24M — down 5.3% from $25.4M a quarter earlier.
Fund positioning in TCON was balanced in Q1 2022: 5 funds opened new positions, 5 closed out, 10 added to existing stakes and 7 trimmed.
The largest buyer was Linden Advisors, adding an estimated $429K. The largest seller was Renaissance Technologies, cutting an estimated $457K.
- 35 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $24M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q1 2022, down 5.3% quarter-over-quarter.
- 5 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q1 2022 and 5 closed out, a net change of 0 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q1 2022 was Linden Advisors, an estimated $429K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q1 2022 was Renaissance Technologies, an estimated $457K sold.
Based on aggregated 13F filings for Q1 2022.